Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis

MUMING YU1*, BIN LU1*, YANCUN LIU1, YING ME1, LIJUN WANG1 and HUI LI2

1Emergency Department, Tianjin Medical University General Hospital, Tianjin 300052; 2Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China

Received October 24, 2015; Accepted November 24, 2016

DOI: 10.3892/mmr.2017.6136

Abstract. Tumor cells resistant to anoikis are considered to be candidates for metastasis. In the present study, the role of Tim-3 in anoikis and its influence on the invasion of clear cell renal cell carcinoma (ccRCC) was investigated. Here, polyhydroxylethylmethacrylate (poly-HEMA) was applied to two ccRCC cell lines, 786-O and Caki-2, to induce detachment from the extracellular matrix (ECM). Tim-3 mRNA and protein expression levels were assayed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot, respectively. Anoikis was measured by Ho33342/PI double staining, acridine orange staining, and further determined using the CytoSelect™ 24-well Anoikis Assay kit. Apoptosis was measured using flow cytometry. E-cadherin and N-cadherin protein expression were determined using western blotting and a Chemicon cell invasion assay kit used to quantify the invasive capacity of 786-O and Caki-2 cells. It was demonstrated that detachment from the ECM decreases transcription and the protein expression level of Tim-3 in 786-O and Caki-2 cells compared with control cells. Interference with Tim-3 expression using small interfering RNA exacerbated anoikis in 786-O and Caki-2 cells induced by poly-HEMA treatment. E-cadherin upregulation, N-cadherin downregulation, and ECM detachment-induced reduction in invasion ability were all exacerbated by knockdown of Tim-3. In conclusion, interference with Tim-3 expression may attenuate the invasion of renal cell carcinoma by aggravating anoikis, indicating Tim-3 as a potential therapeutic target for treating ccRCC.

Introduction

Clear cell renal cell carcinoma (ccRCC), a major pathological form of kidney cancer, accounts for ~90% of kidney malignancies (1). There are >200,000 cases diagnosed and >100,000 deaths from kidney cancers annually. Approximately one third of patients display metastasis at diagnosis and thus a poor prognosis, with a 5-year survival rate of <20% for patients with metastasized ccRCC (2). Therefore, understanding the mechanisms of invasion and metastasis in ccRCC is of great importance to public health.

Metastasis is a major cause of mortality in multiple cancers, including ccRCC (3-5). The first stage of tumor metastasis is the detachment of tumor cells from the basement membrane and extracellular matrix (ECM). Normally, the growth of tumor cells is reliant on adherence with the basement membrane and ECM. When the basement membrane and ECM are damaged or degraded, tumor cells detach and enter the circulatory system. Most cells entering the circulatory system face anoikis, a special form of programmed cell death induced by disengagement from the surrounding ECM or adjacent cells and the resultant loss of normal cell-matrix interactions. Anoikis is an important contributor to development, disease and tumor metastasis (6,7). Resistance to anoikis is a critical characteristic of metastatic tumor cells, but the mechanisms underlying this remain largely unknown, particularly in ccRCC.

Tim-3 is an important member of the T cell immunoglobulin and mucin domain-containing molecule family (8). It has been reported to impact multiple diseases, especially human tumor biology: Tim-3 was reported to participate in colon cancer tumorigenesis and its expression was hypothesized to be an independent prognostic factor for patients with colorectal cancer (9). Tim-3 also affected the development and progression of prostate cancer (10). Increasing evidence suggests that Tim-3 is involved in maintaining the malignant phenotype of ccRCC progression, but the mechanisms behind this require further investigation (11). Previous studies have demonstrated that anoikis impair RCC (12), but to the best of our knowledge, no study has yet examined the effect of Tim-3 on anoikis sensitivity in ccRCC.

The present study investigated the involvement of Tim-3 in anoikis and its influence on the invasion of the ccRCC cell lines, 786-O and Caki-2. Detachment from the ECM was induced.

Key words: Tim-3, renal cell carcinoma, invasion, metastasis, anoikis

Correspondence to: Professor Muming Yu, Emergency Department, Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin 300052, P.R. China
E-mail: muming_yu@126.com

*Contributed equally
by polyhydroxylethylmethacrylate (poly-HEMA) treatment, and anoikis was measured by morphological observation, flow cytometry and a CytoSelect™ 24-well Anoikis Assay kit in the presence and absence of Tim-3 small interfering RNA (siRNA). Interference with Tim-3 expression increased ECM detachment-induced anoikis and reduced the invasive ability of ccRCC cells. Therefore, interference with Tim-3 expression may attenuate ccRCC invasion, and therefore metastasis, through increasing sensitivity to anoikis.

Materials and methods

Materials. Caki-2 and 786-O human ccRCC cell lines were purchased from the American Tissue Type Collection (Manassas, VA, USA). RPMI-1640 medium and fetal bovine serum (FBS) were obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Anti-Tim-3 (cat. no. sc-30326), E-cadherin (cat. no. sc-71007), N-cadherin (cat. no. sc-59987) and β-actin (cat. no. sc‑74778) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Tim-3 specific siRNA (cat. no. sc‑72034) and a negative control siRNA (cat. no. sc-108060) were purchased from Santa Cruz Biotechnology, Inc. The cell invasion assay kit used was from Chemicon (Merck Millipore) and the CytoSelect™ 24-well Anoikis Assay kit (cat. no. CBA-080) was from Cell Biolabs, Inc. (San Diego, CA, USA). The kit provides an MTT colorimetric system to detect the growth and viability of cells detached from extracellular matrix. Cells in each group were seeded (1x10^5/well) in the 24-well cell culture plate pre-coated with poly-HEMA solution (0.5 ml/well), and each group was treated as described above. MTT Reagent (50 µl) was added into each well, and incubated for 2-4 h at 37°C. Then, detergent solution (500 µl) was added to each well, and was mixed gently by pipetting. The wells were incubated for another 2-4 h in the dark at room temperature. A total of 200 µl of the incubated solution was added to a 96-well plate, and the absorbance was measured at 570 nm using an ELISA reader (Multiskan GO, Thermo Fisher Scientific, Inc.). The absorbance value reflected the relative viability of each well under anoikis.

Cell culture. Caki-2 and 786-O cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg streptomycin at 37°C in a humidified atmosphere with 5% CO₂. Passage digestion was conducted by 0.25% trypsin.

Preparation of poly-HEMA-coated plate. Poly-HEMA powder was dissolved in 95% ethanol in a 65°C water bath. The poly-HEMA solution (1 ml, 52.2 mg/ml) was then sterilized under a 0.22 µm membrane and added to each culture well (12-well/plate), and incubated overnight at room temperature. The plates were washed 2-3 times with sterile double distilled H₂O prior to use.

Interference of Tim-3 expression with Tim-3 siRNA. As described previously, the target sequences used for Tim-3 interference were Tim-3 siRNA #1 (SASI_Hs01_00114252) (8). 786-O and Caki-2 cells were cultured to 70% confluence. Cells were transfected with 100 pmol siRNA using Lipofectamine RNAiMax (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Total protein was extracted 48 h post-transfection and western blots were performed as described below to analyze protein levels of target genes.

Cell groups. Cells were divided into three groups: Control group (786-O or Caki-2 cells seeded into normal wells (1x10^5/well) in the absence of poly-HEMA pre-coating, the poly-HEMA treated group (786-O cells or Caki-2 cells cultured in poly-HEMA pre-coated wells, 1x10^5/well) and the poly-HEMA + siRNA combined group (786-O cells or Caki-2 cells (1x10^5/well) cultured in the poly-HEMA pre-coated wells and transfected with Tim-3 siRNA for 24 h. The negative control group (786-O cells or Caki-2 cells cultured in the poly-HEMA pre-coated wells (1x10^5/well) were transfected with negative control (NC) siRNA for 24 h).

Morphological observation. Hoechst 33342 (Ho33342)/propidium iodide (PI) double staining and acridine orange staining were conducted to observe morphological changes in anoikitic cells. Prior to staining cells were washed twice with PBS, fixed with 10% methanol for 15 min, and stained by Ho33342 (10 µg/ml) and PI (50 µg/ml) at 37°C for 30 min, or acridine orange (1 mg/ml) at room temperature for 15 min. Morphological changes were examined by fluorescence microscope at x200 magnification. In Ho3342/PI staining, cells displaying blue nuclear fragmentation were interpreted as apoptotic cells, while cells with red were defined as necrotic. In acridine orange staining, bright green fluorescence and orange-red fluorescence is seen in DNA and RNA, respectively, based on the membrane permeability of the cells.

Flow cytometry. 786-O and Caki-2 cells were seeded and treated as described above (1x10^5/well). Prior to detection, 786-O and Caki-2 cells were washed with PBS without fixation and resuspended in 200 µl binding buffer containing Annexin V FITC (5 µl) and PI (10 µl) for 15 min at room temperature. Further binding buffer (300 µl) was added prior to analysis with a FACScan flow cytometer (BD Biosciencies, Franklin Lakes, NJ, USA). The FlowJo software (version, 7.6; FlowJo, LLC, Stanford, CA, USA) was used for further data analysis. Flow cytometry analysis was used for cell apoptosis determination.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RNA extraction and RT-qPCR were performed as described previously (8). β-actin was used as a normalization control. All experiments were performed in triplicate. The primers used were as follows: Tim-3, forward 5'-GCTACTCTTCAAGGTCCTCAG-3' and reverse 5'-ATTACATCCCTTTTTCATCAGTC-3'; β-actin, forward 5'-TGGCACCCCGAACAATGGA-3' and reverse 5'-CTAAGTCATAGTCCGCCTAGAAGC-3'.

Western blot analysis. Cells were harvested 48-72 h following transfection in each group. Cells were lysed under radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) on ice for 30-40 min, vortexing every 5-10 min. Then, cells were centrifuged at 4°C for 15 min (13,225 x g). The supernatant was the protein extraction. Protein concentration was determined using a bicinchoninic acid assay. Subsequently, 40 µg protein was run on 10% SDS-PAGE gel and transferred to polyvinylidene fluoride membranes. The membranes were incubated with primary antibodies, followed by secondary antibodies and antigens were detected using an enhanced chemiluminescence chemiluminescence kit (Thermo Scientific, Inc.). The signal intensity was quantified using Image J software.
fluoride (PVDF) membranes. PVDF membranes were blocked with 10% skim milk in TBST for 1 h at room temperature and incubated overnight at 4°C with primary antibodies (all purchased from Santa Cruz Biotechnology, Inc.), including Tim-3 (1:1,000, cat. no. sc-30326), E-cadherin (1:200, cat. no. sc-71007), N-cadherin (1:200, cat. no. sc-59987), and β-actin (1:500, cat. no. sc-47778). Secondary antibodies goat anti-mouse IgG conjugated to horseradish peroxidase (HRP); cat. no. sc-2055) and goat anti-rabbit IgG-HRP (cat. no. sc-2004) were added for further incubation with the membrane of 1 h at room temperature (1:5,000) and Western Blot Luminal Reagent (CWbio Co., Ltd., Beijing, China) were used to visualize the protein bands, and protein levels were quantified by densitometric analysis using Image J software (version, 1.42; National Institutes of Health, Bethesda, MA, USA). All experiments were repeated at least three times.

**Detectors of invasive ability.** Invasive abilities were detected based on the Chemicon cell invasion assay kit (8 μm pore size) as described by Li et al (13). Serum-free medium (300 μl) was added onto the surface of the insert and incubated for 2 h to rehydrate. Medium containing 10% FBS (500 μl) was added to each well beneath the insert as the chemotactrant. The upper wells were seeded with 100 μl 786-O or Caki-2 cell suspension, containing ~50,000 cells. Following 24 h incubation at 37°C, cells were fixed with 2% paraformaldehyde at room temperature for 15 min and stained cells in lower chamber with 0.25% crystal violet at room temperature for 10 min. The stained cells were dissolved using 10% acetic acid at room temperature for 10 min, and the absorbance of the mixture at 560 nm was assayed under a microplate reader. All experiments were performed in triplicate.

**Statistical analysis.** Data are presented as the mean ± standard deviation and were analyzed using the statistical package SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). The significance of differences between groups was determined using two-tailed Student's t-tests. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Detachment from the ECM decreases Tim-3 mRNA and protein expression levels.** 786-O and Caki-2 cells were seeded in poly-HEMA pre-coated wells to induce ECM detachment. Total RNA and proteins were extracted from control and poly-HEMA-treated cells, and the transcription and expression of Tim-3 were analyzed using RT-qPCR and Western blotting. The Tim-3 transcription level decreased significantly in poly-HEMA treated 786-O and Caki-2 cells compared with control cells (P=0.038 and P=0.024, respectively; Fig. 1A). Detachment from the ECM also significantly decreased Tim-3 protein expression levels in 786-O and Caki-2 cells compared with control cells (P=0.016 and P=0.035, respectively; Fig. 1B and C). This indicates that expression of Tim-3 in ccRCC cells may be associated with anoikis.

**Interference with Tim-3 expression reduced the cell viabilities of ccRCC cells.** Tim-3 expression was blocked with siRNAs, with Tim-3 siRNA successfully inhibiting the expression of Tim-3 in 786-O cells (36.58±7.65%, P=0.009 vs. control) and in Caki-2 cells (45.04±4.23%, P=0.024) (Fig. 2A and B). Cell ability was determined using the CytoSelect™ 24-well Anoikis Assay kit. Detachment from the ECM (poly-HEMA group cells) significantly reduced the activities of 786-O cells and Caki-2 cells compared with control cells, with OD570 nm values as follows: Control 786-O cells, 0.42±0.03, poly-HEMA treated 786-O cells, 0.23±0.044 (P=0.037); control Caki-2 cells, 0.4±0.051, poly-HEMA treated Caki-2 cells, 0.28±0.025 (P=0.018; Fig. 2C). Knockdown of Tim-3 expression reduced activities further, with recorded OD570 nm values as follows: Poly-HEMA-treated + siRNA 786-O cells, 0.15±0.015 P=0.021 vs. poly-HEMA treated cells; poly-HEMA treated + siRNA Caki-2 cells, 0.14±0.021; P=0.038 vs. poly-HEMA treated cells (Fig. 2C). Cells under anoikis show reduced activities, so the lower the measured OD value, the higher anoikis of cells occurred.

**Tim-3 downregulation causes morphological changes in ccRCC cells.** Following Ho33342/PI double staining, control cells appeared blue with intact nuclei, while poly-HEMA treated cells demonstrated suspension and aggregation, with non-intact blue nuclei. Cells transfected with Tim-3 siRNA displayed more damaged blue nuclei or PI-stained red nuclei (Fig. 3A). In acridine orange staining, the nuclei of control cells appeared intact, and poly-HEMA treated cells displayed more damaged nuclei (Fig. 3B). This was exacerbated by Tim-3 siRNA transfection (Fig. 3B). Thus, detachment from the ECM induces anoikis, and knockdown of Tim-3 expression increased anoikis further.
Knockdown of Tim-3 expression significantly increased apoptosis. For 786-O cells, apoptosis rate was increased in the poly-HEMA treatment group (5.37±0.67%) and the poly-HEMA treatment + siRNA group (9.83±0.93%) compared with the control group (1.97±0.21%) (P=0.041 and P=0.015, respectively). In addition, a significant difference was identified between the poly-HEMA treatment group and the poly-HEMA treatment + siRNA group (P=0.025).

Knockdown of Tim-3 expression decreased invasion of ccRCC cells. Poly-HEMA treated 786-O cells demonstrated significantly decreased invasive abilities compared with control cells, with 560 nm absorbance values of 0.113±0.015 in poly-HEMA cells and 0.243±0.04 in control cells (P=0.022; Fig. 6). RNAi-mediated silencing of Tim-3 aggravated this reduction, with a 560 nm absorbance value of 0.073±0.012 (P=0.003 vs. control group; P=0.011 vs. poly-HEMA treatment group; Fig. 6). Similar results were observed in Caki-2 cells, with 560 nm absorbance values recorded as 0.263±0.015 for the control group and 0.147±0.015 for the poly-HEMA treatment group (P=0.005; Fig. 6), and 0.08±0.01 for the poly-HEMA treatment + siRNA group (P=0.016 vs. control group, P=0.018 vs. poly-HEMA treatment group; Fig. 6).

Discussion

The results of the present study suggest that Tim-3 expression is involved in the process of anoikis in ccRCCs, which may influence their invasion ability and, thus, their metastatic potential. Knockdown of Tim-3 expression exacerbated anoikis in 786-O and Caki-2 cells, which displayed obvious morphological changes and increased apoptosis ratios as measured by flow cytometry. In addition, interference with Tim-3 expression
attenuated the invasion of 786-O and Caki-2 cells, increased E-cadherin expression and decreased N-cadherin expression. To the best of our knowledge, few studies have investigated the role of Tim-3 in anoikis, especially in ccRCC. These results provide novel insights regarding the function of Tim-3 in tumor biology.

ccRCC is the most frequently occurring kidney cancer, with high rate of metastasis through the blood circulation. It has previously been reported that ~33% of patients with ccRCC displayed metastasis at diagnosis, resulting in poor prognosis and a low 5-year survival rate (14). However, previous studies have demonstrated the prognosis of RCC improves when the expression of a number of genes is targeted, including Tim-3 (15,16).

Tim-3 expression levels are increased in ccRCC tissue compared with adjacent normal renal tissue (17) and high levels of Tim-3 expression are considered as an independent predictor of ccRCC-specific survival and progression-free survival (11). Previous research has indicated that Tim-3 is
involved in the invasive potential of ccRCC cells, by either activating or inhibiting GATA binding protein 3 (8). The results of the present study further confirm the involvement of Tim-3 in the invasion ability of ccRCC cells, indicating Tim-3 as a potential therapeutic target for treating ccRCC. This is consistent with the work of Yuan et al (11).

Anoikis-resistant carcinoma cells are a cause of metastasis in cancers, including ccRCC. Cancer cell growth relies on adherence with an intact basement membrane and ECM, which are essential for their growth. Damage to the basement membrane or ECM results in an unfavorable environment for cell growth. Cells detached from the basement membrane or ECM undergo anoikis, and only cells that escape anoikis enter the blood circulation and ultimately form metastases. Therefore, anoikis resistance is critical for tumor metastasis. Previous research has reported certain factors that modulate anoikis sensitivity and resistance in ccRCC, including histone deacetylase inhibitors (18), tumor progression locus 2 kinase (19), and HMGA1 (20). Further mechanisms of anoikis sensitivity and resistance in ccRCC remain unknown. The present study demonstrated morphological changes to cancer cells using Ho33342/PI double staining and acridine orange staining, assayed the apoptosis rate by flow cytometry analysis, and measured the rate of anoikis using the CytoSelect™ 24-well assay kit. It was revealed that knockdown of Tim-3 enhanced the rate of anoikis in 786-O and Caki-2 cells, indicating that Tim-3 is an anoikis inhibitory molecule. To the best of our knowledge, this is the first time Tim-3 has been demonstrated to modulate anoikis in ccRCC.

The present results provided novel insights into the role of Tim-3 in ccRCC anoikis. However, little has been examined regarding the molecular mechanism involved in Tim-3-mediated anoikis. Neither of the core cell apoptosis pathways, including the extracellular pathway (death receptor pathway) and intracellular pathway (mitochondrial pathway), were involved in the present study. Future studies concerning the cell apoptosis pathway involved in Tim-3-mediated anoikis will be of great value to the field.

To summarize, the present study demonstrated that interference with Tim-3 expression using siRNA may attenuate ccRCC invasion by aggravating anoikis following cell detachment, indicating Tim-3 might be a potential target for treating ccRCC.

References

1. la Rosa AH, Acker M, Swain S and Manoharan M: The role of epigenetics in kidney malignancies. Cent European J Urol 68: 157-164, 2015.
2. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF and Belldegrun AS: Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 178: 1189-1195, 2007.
3. Liu B, Wen X and Cheng Y: Survival or death: Disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis 4: e892, 2013.
4. Criscitiello C, Esposito A and Curigliano G: Tumor-stroma crosstalk: Targeting stroma in breast cancer. Curr Opin Oncol 26: 551-555, 2014.
5. Sato H, Hagiwara H, Ohide Y, Senba H, Virgona N and Yano T: Regulation of renal cell carcinoma cell proliferation, invasion and metastasis by connexin 32 gene. J Membr Biol 216: 17-21, 2007.
6. Paolli P, Giannoni E and Chiariu RG: Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833: 3481-3498, 2013.
7. Strauss SJ, Ng T, Mendoza-Naranjo A, Whelan J and Sorensen PH: Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist 15: 627-635, 2010.
8. Zheng H, Guo X, Tian Q, Li H and Zhu Y: Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma. Int J Clin Exp Med 8: 7029-7038, 2015.
9. Zhou E, Huang Q, Wang J, Fang C, Yang L, Zhu M, Chen J, Chen L and Dong M: Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol 8: 8018-8027, 2015.
10. Xiao YR, Jin ZH, Yuan KC and Jin XS: Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol 35: 11409-1480, 2014.
11. Yuan J, Jiang B, Zhao H and Huang Q: Prognostic implication of TIM-3 in clear cell renal cell carcinoma. Neoplasma 61: 35-40, 2014.
12. Sakamoto S, Schwarze S and Kyripanou N: Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol 59: 734-744, 2011.
13. Li L, Jiang AC, Dong P, Wang H, Xu W and Xu C: MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol 16: 1421-1428, 2009.
14. Yang YQ and Chen J: Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients. Genet Mol Res 13: 5011-5017, 2014.
15. Cai C, Wang L, Wu Z, Li M, Chen W and Sun Y: T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA Cell Biol 31: 1285-1289, 2012.
16. Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzzi S, Kinoshita I, et al: The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res 3: 999-1007, 2015.
17. Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermans T, Hefermehl L, Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermans T, Hefermehl L, Schraml P, Moch H, et al: Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2: e23562, 2013.
18. Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB and Dent P: Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biol Ther 14: 1039-1049, 2013.
19. Lee HW, Joo KM, Lim JE, Cho HJ, Cho HJ, Park MC, Seol HJ, Seo SI, Lee JI, Kim S, et al: TpII kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. Mol Cancer Res 11: 1375-1386, 2013.
20. Takaha N, Sowa Y, Takeuchi I, Hongo F, Kawauchi A and Miki T: Expression and role of HMGA1 in renal cell carcinoma. J Urol 187: 2215-2222, 2012.